Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of rituximab cerebrospinal fluid concentrations in primary central nervous system lymphoma
ChiCTR1900021415Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Cerebrospinal fluid concentration of rituximab. Started Dec 2016; status: completed.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR1900021415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021415.